Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.
Stage-specific survival of screen-detected versus clinically diagnosed colorectal cancer - evidence from the FOBT screening trials- Iris Lansdorp-Vogelaar.
FEMALE BREAST CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/03/20014.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/02/2013.
PROSTATE CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/01/2013.
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
MELANOMA JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.
LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.
PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.
Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.
The Burden of Cancer in Connecticut Lou Gonsalves Connecticut Tumor Registry
Johns Hopkins Hospital Cancer Registry Melanoma
JHH Prostate Cancer Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Presented By Alan Venook at 2016 ASCO Annual Meeting
Patient & tumor characteristics (n=39)
What does the data tell us? Colorectal CANCER IN NEVADA
CCO Independent Conference Coverage
NON-SMALL CELL LUNG CANCER
Prognostic significance of tumor subtypes in male breast cancer:
Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.
Surveillance Research Program
Securing the cure in resectable lung cancer
JOHNS HOPKINS HOSPITAL CANCER REGISTRY
Presented By Michael Lee at 2016 ASCO Annual Meeting
JOHNS HOPKINS CANCER REGISTRY 2009
ANALYTIC PANCREATIC CANCER by CLASS N = 369
Johns Hopkins Hospital Cancer Registry
LL Gunderson1, JM Jessup 2, DJ Sargent 3, FL Greene 4, A Stewart 5
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
6 Cancer survival Ontario Cancer Statistics 2018 Chapter 6: Cancer survival.
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
4 Relative survival Ontario Cancer Statistics 2016 Chapter 4: Relative survival.
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
Estimated current cancer incidence
Volume 152, Issue 8, Pages e3 (June 2017)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
4155 primary hepatocellular carcinoma with known diagnosis month/year
Physical Activity and Endometrial Cancer Survival
Treating Leukemia in Youths
Published online September 20, 2017 by JAMA Surgery
National Cancer Statistics in Korea, 2015
Raymond N. DuBois, M.D., Ph.D. Executive Director
Physical Activity and Endometrial Cancer Survival
Caitlin C. Murphy, Kristin Wallace, Robert S. Sandler, John A. Baron 
Ali Shamseddine,MD,FRCP
UK Renal Registry 16th Annual Report
Presented By Joshua Richter at 2016 ASCO Annual Meeting
Lung Cancer (C33-C34): 2011 Proportion of Cases Diagnosed at Each Stage, Adults (Aged 15-99), England and Wales Stage Adults Stage I 14.5% Stage II 7.3%
Trends in survival from metastatic lung cancer in California,
Colorectal cancer survival disparities in California
Nadia Howlader, PhD National Cancer Institute
Presentation transcript:

Presented By Deborah Schrag at 2016 ASCO Annual Meeting The Association Between Primary Tumor Location and Survival in Colorectal Cancer Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Study Motivation Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Study Objective Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Study Data Sources: <br />18 Tumor Registries in NCI‘s SEER Program since 2000<br />Linkage to Medicare Enrollment and Claims Data Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Study Methods Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Categorization of Colorectal Primary Sites<br /> Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Tumor Location and Age, Stage At Diagnosis Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Stage IV Colorectal Cancer <br />by Primary Tumor Location and Year of Diagnosis<br /> Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival for Stage IV CRC from SEER <br />by Tumor Location, 2000-2012 Diagnoses Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival for Stage IV CRC in SEER<br />by Primary Tumor Location, 2000-2012 Diagnoses Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival for Stage IV CRC <br />by Primary Tumor Location and Year of Diagnosis<br /> Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting <br />Stage IV CRC Median Survival in Months<br />by Primary Tumor Location and Year of Diagnosis Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival in Stage III CRC <br />by Primary Tumor Location, 2000-2012 Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival for Stage III CRC <br />by Primary Tumor Location and Year of Diagnosis Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Stage III CRC Median Survival in Months<br />by Primary Tumor Location and Year of Diagnosis Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival in Stage II CRC <br />by Primary Tumor Location, 2000-2012 Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Is the Association Between Sidedness and Prognosis All Lead Time? Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Stage III CRC By Primary Tumor Location and Substage Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Overall Survival for Stage III CRC <br />by tumor location and AJCC sub-stage Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting <br />Stage IV subgroup diagnosed 2004-2011 enrolled in Medicare and treated with Cetuximab or panitumumab ascertained from Medicare claimss<br /> Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Stage IV: Survival from first dose of Cetuximab/P-mab Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Discussion: Relating Phenotype to Genotype<br />Consensus Molecular Subtypes in Colorectal Cancer Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Discussion: Relating Phenotype to Genotype<br />Consensus Molecular Subtypes Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Study Conclusions Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting THANK YOU! Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Presented By Deborah Schrag at 2016 ASCO Annual Meeting Stage III Colorectal Cancer <br />by Primary Tumor Location and Year of Diagnosis Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Stage IV CRC: <br />Adjusted Hazard Ratios for Overall Survival Presented By Deborah Schrag at 2016 ASCO Annual Meeting